List view / Grid view
8 April 2016 | By Victoria White, Digital Content Producer
Researchers identified a new gene called FOXF2 which increased the risk of having a stroke due to small vessel disease in the brain...
7 April 2016 | By Victoria White, Digital Content Producer
Allergan is to license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development by Heptares...
17 March 2016 | By Victoria White
Scientists have developed a capsule containing cells that have been genetically engineered to produce antibodies against the Abeta...
17 March 2016 | By Drug Target Review
In this Drug Targets In-Depth Focus: "The alarming increase in antibioticresistant bacteria", plus "Computational methods for drug repositioning"; and "An overview of Alzheimer’s disease drug targets"...
1 March 2016 | By Victoria White
Using pexidartinib to flush away the inflammatory cells produced in reaction to beta-amyloid plaques, scientists restored memory function in test mice...
1 March 2016 | By Victoria White
The AChE peptide has been shown to drive production of both amyloid and hyperphosphorylated tau in Alzheimer's disease...
26 February 2016 | By Victoria White
Researchers have developed a targeted substance that blocks the pathogenic function of an enzyme that is partly responsible for Alzheimer’s disease without affecting its other vital functions...
16 February 2016 | By Victoria White
AbbVie has been announced as the latest Dementia Consortium partner, joining MRC Technology, Alzheimer’s Research UK, Astex, Eisai and Lilly...
21 January 2016 | By Hans Fliri PhD, Chairman, Cypralis
Here, Dr Hans Fliri, Chairman and CEO of Selcia and Chairman of Cypralis, presents a strong case for targeting mitochondrial cyclophilin D to prevent progression of chronic neurodegenerative diseases...
21 January 2016 | By Victoria White
MRCT will identify projects with the greatest promise for advancement as investigational therapies and advise the Alzheimer's Association on strategies for moving them forward such that they realise the maximum potential...
13 January 2016 | By Victoria White
Boehringer Ingelheim and Arena Pharmaceuticals have signed an exclusive agreement to conduct joint research to identify drug candidates for psychiatric diseases...
7 January 2016 | By Nicholas Jackson
Plans for the world’s first clinical trial for a vaccine targeting Alzheimer’s disease-like characteristics in those with Down's syndrome have been announced...
4 January 2016 | By Victoria White
BPN14770 may be a possible treatment for dementia and Alzheimer’s disease with less potential for side effects than rolipram...
22 December 2015 | By Victoria White
A study suggests that enhancing proteasome activity with drugs during the early stages of Alzheimer’s may prevent dementia and reduce damage to the brain...
22 December 2015 | By Victoria White
The IMI has launched two Calls for proposals that will advance drug development in Ebola, childhood cancers, neurological disorders, and eye disease...
